LITTLE FALLS, N.J.,
April 25, 2012 /PRNewswire/
-- CANTEL MEDICAL CORP. (NYSE:CMN) announced today the
appointment of Seth M. Yellin as
Vice President of Corporate Development. Mr. Yellin will lead
Cantel's active acquisition program and be heavily involved in
strategic planning.
Mr. Yellin, 37, has been a healthcare industry analyst and
investment professional for over ten years. Most recently, he
was responsible for equity investment coverage of the medical
device and life science tools industries at Citadel Asset
Management. Previously he was an M&A specialist at UBS
Investment Bank. Mr. Yellin received a BA from Princeton University and an MBA from The Wharton
School at the University of
Pennsylvania.
"Seth's experience as a healthcare investor and investment
banker brings a valuable skill set to our organization and makes
him well qualified to direct Cantel's acquisition program and other
corporate development activities," said Andrew Krakauer, President and CEO of Cantel
Medical.
Cantel Medical Corp. (NYSE:CMN) is a leading provider of
infection prevention and control products in the healthcare market.
Our products include water purification equipment,
sterilants, disinfectants and cleaners, specialized medical device
reprocessing systems for endoscopy and renal dialysis, disposable
infection control products primarily for dental and GI endoscopy
markets, dialysate concentrates and other dialysis supplies, hollow
fiber membrane filtration and separation products for medical and
non-medical applications, and specialty packaging for infectious
and biological specimens. We also provide technical
maintenance for our products and offer compliance training services
for the transport of infectious and biological specimens. For
further information, visit the Cantel website at
www.cantelmedical.com.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements involve a number of risks and uncertainties,
including, without limitation, the risks detailed in Cantel's
filings and reports with the Securities and Exchange Commission.
Such forward-looking statements are only predictions, and actual
events or results may differ materially from those projected or
anticipated.
SOURCE Cantel Medical Corp.